dallas semaglutide intestinal paralysis lawsuit Ozempic Lawsuit: August 2026 Blindness and Gastroparesis Claims dallas semaglutide bowel obstruction law

Clinicians may have preferentially prescribed GLP-1RAs to patients with better-controlled IBD ( Managing clinical friction points If clinicians are to leverage GLP-1RAs, they must manage practical friction points

Additional safety considerations include tirzepatide's boxed warning for thyroid C-cell tumors, risk of pancreatitis (symptoms include severe persistent abdominal pain, sometimes radiating to the back), gallbladder disease, and potential complications in patients with diabetic retinopathy

This dual mechanism is why tirzepatide doses start at 2.5 mg while semaglutide starts at 0.25 mg

Efficacy comparison Injectable semaglutide has the strongest evidence base

10.1016/j.soard.2009.09.012 168 PeukerE